SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is experiencing significant market volatility and social media attention as the community fixates on the upcoming Artemis II mission and the company's critical role in NASA's lunar infrastructure. Investors are debating the impact of recent institutional filings and broader macroeconomic instability, while the community remains polarized between those anticipating a major breakout tied to launch success and others bracing for continued price fluctuations.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is experiencing intense investor scrutiny ahead of an earnings report, with community sentiment divided between speculation of a potential SpaceX-led buyout and skepticism over the company's long-term profitability. Investors are closely tracking rumors of a SpaceX IPO and potential spectrum acquisition as a key catalyst for volatility.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is facing intense scrutiny as investors weigh the stock's resilience against heightened geopolitical tensions and uncertainty surrounding the conflict in the Middle East. While community sentiment is deeply divided, ongoing debates highlight a sharp contrast between long-term confidence in the company's cloud and infrastructure dominance and short-term anxieties regarding market volatility and institutional sell-offs.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently seeing significant momentum driven by growing anticipation surrounding a potential SpaceX IPO, which investors view as a major catalyst for the entire space sector. The community is actively debating the stock's long-term infrastructure potential and institutional outlook, while sentiment remains highly positive regarding Peter Beck's leadership and the company's expanding contract backlog.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is facing intense scrutiny from investors as persistent concerns over leadership communication, the delayed update on the Helios data center project, and the stock's tendency to underperform relative to crypto sector gains dominate community discourse. While some traders view the current price action as a buying opportunity based on long-term data center potential and institutional interest, many others are expressing frustration through comparisons to previous market failures, highlighting a significant divide between institutional conviction and retail sentiment.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire is currently trending as traders closely monitor technical resistance near the $10 level, while balancing persistent selling pressure from private equity firms with excitement over new defense contract wins and NASA's Artemis mission. The community remains heavily divided between long-term bulls betting on the company's space infrastructure growth and frustrated retail investors navigating high volatility and the frequent failure of recent breakout attempts.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is gaining attention as community members discuss the company's competitive position in the obesity drug market, particularly following recent phase three trial enrollment updates and perceived limitations in competitor data. Investors are closely monitoring the potential for a strategic partnership or buyout, viewing the firm's metabolic drug pipeline as a high-value asset amid broader sector-wide interest in obesity therapeutics.

Launchr is a programmable creator fee engine designed to adapt to every stage of a token’s lifecycle.  Instead of hard coded splits or one time choices, Launchr lets creators dynamically route fees in real time based on market conditions, liquidity depth, and strategy.

Launchr

LAUNCHR is capturing significant speculative attention as the community rallies around an imminent project launch, frequently associating the token with high-profile space exploration themes and viral social media momentum.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera (HBAR) is currently attracting significant retail interest as traders view current price levels as a generational accumulation opportunity ahead of anticipated regulatory clarity and institutional adoption. The community is actively debating the impact of the upcoming Digital Asset Market Clarity Act while weighing the potential for enterprise integration against concerns regarding circulating supply.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently under intense scrutiny as a major security exploit involving the Drift Protocol has triggered widespread community concern and selling pressure, overshadowing positive developments like institutional stablecoin integrations. Investors remain divided, with some actively buying the dip while others debate the network's long-term resilience against growing FUD and market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Assenagon Asset Management S.A. trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 88.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 359,580 shares of the biotechnology co...

BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 28.5% during the 3rd quarter, according to its most recent 13F filing with the...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up - What's Next?

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up - Should You Buy...

<ul class="summary-bullets"><li>Elevated oil prices and Middle East tensions are keeping traders on the edge.</li><li>Investors are eyeing PMI data and GameStop earnings as near-term catalysts for market direction.</li><li>AI stocks remain in focus amid fresh supply chain concerns and geopolitical scrutiny around chip exports.</li></ul>U.S. stock futures rose early Tuesday, attempting to build on the recovery seen in the previous market session. However, investors remain cautious amid the uncertainty in the Middle East. Traders will also be watching for cues from manufacturing data due this morning and Gamestop earnings later today.&nbsp;Crude oil prices rose on concerns that the Iran conflict could reportedly expand to U.S. allies in the Persian Gulf. This comes even as Iranian lawmakers dismissed the possibility of negotiations with the U.S. As of 4:30 a.m. ET on Tuesday, Dow and S&amp;P 500 futures rose 0.2%, and Nasdaq and Russell 2000 futures were up 0.3%.Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, remained ‘extremely bearish, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has remained ‘bearish’ amid high trading volume.&nbsp;Trending Stocks To Watch Nvidia (NVDA):&nbsp;Following the SMCI crisis, U.S. Senators are reportedly demanding a suspension of the AI bellwether’s GPU export licenses to China and Southeast Asia.&nbsp;Broadcom (AVGO):&nbsp;The chipmaker has reportedly warned that its manufacturing partner, TSMC, is nearing capacity for the year, adding to supply concerns.&nbsp;Oracle (ORCL) and Alibaba (BABA):&nbsp;Reports suggest they have launched significant “agentic AI” initiatives.&nbsp;Alibaba has unveiled a new chip design, while Oracle is said to be embedding AI agents in its cloud-based financial software.&nbsp;Amazon (AMZN):&nbsp;The company has said its Bahrain AWS region has been disrupted by drone activity in the Middle East.&nbsp;Gamestop (GME):&nbsp;The video game retailer reports earnings after the bell today. Investors will be tracking any updates on its Bitcoin treasury or an AI-driven pivot.BioCryst Pharmaceuticals (BCRX): The stock is garnering heavy retail attention following takeover speculation.Applied Optoelectronics (AAOI):&nbsp;The stock was trending on Stocktwits following confirmation of a $53 million order for its 800G data center transceivers.&nbsp;Vertiv Holdings Co. (VRT): The stock is on retail radar after it agreed to acquire Italy-based ThermoKey.&nbsp;And&nbsp;Estee Lauder&nbsp;(EL)&nbsp;is reportedly exploring a merger with Puig. Other tickers trending on&nbsp;Stocktwits&nbsp;at the time of writing included Intuitive Machines (LUNR), Micron Technologies (MU), Fastly Inc (FSLY), and The Metals Company (TMC).&nbsp;Other Catalysts To WatchOn the economic front, investors will be tracking the S&amp;P Global Manufacturing &amp; Services PMI at 9:45 am ET. Also, watch out for commentary from&nbsp;Fed Vice Chair for Supervision&nbsp;Michael Barr‘s speech at 6:30 pm ET.&nbsp;On earnings radar, watch out for quarterly reports from&nbsp;Achieve Life Sciences Inc.(ACHV), Greenland Technologies Holding Corp (GTEC), and Huami Corp (ZEPP), before the bell. Meanwhile.&nbsp;Fortress Biotech Inc (FBIO), Durect Corp (DRRX), and Scienture Holdings Inc. (SCNX) are among other companies reporting after market close today.&nbsp; For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Rise Ahead Of PMI Data, Iran Tensions Cap Risk Appetite: Why NVDA, GME, AAOI, BCRX Are Keeping Traders Engaged Today

Data from Stocktwits indicated that retail sentiment has remained bearish on SPY and QQQ for over a week. 

Equity

Data from Stocktwits indicated that retail sentiment has remained bearish on SPY and QQQ for over a week. 


BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the thirteen brokerages that are presently covering the stock, MarketBeat...

<ul class="summary-bullets"><li>Retail traders debated the timing and pricing of the buyout, with some expecting an all-cash offer and others speculating about various takeover scenarios.</li><li>Skeptical users noted BioCryst’s history as an acquirer and argued shares would likely trade closer to $14-$15 if firm deal insights existed.</li><li>The company's growth remains anchored by Orladeyo, which generated $601 million in revenue and $214 million in non-GAAP operating profit last year.</li></ul>Shares of BioCryst Pharmaceuticals, Inc. (BCRX) jumped about 11% in after-hours trading on Monday as retail sentiment hit its strongest level of 2026 and volumes doubled, fueling speculation that a U.S. biopharma worth over $15 billion could be circling the company.<a href="https://stocktwits.com/symbol/BCRX">BCRX stock</a> ended over 1% higher at $9.8 on Monday, with shares up 23% over the past year.<h2 class="st-heading-2">Retail Investors Weigh Buyout Odds For BCRX</h2>The renewed takeover buzz followed last week's reports of a Betaville “uncooked” alert, which said that a party interested in BioCryst may be a U.S.-based biopharma firm with a market cap exceeding $15 billion.&nbsp;Among the biotech companies with a market cap between $15 billion and $20 billion are Incyte Corp., Revolution Medicines, Inc., Roivant Sciences Ltd., and Exact Sciences Corp.On Stocktwits, retail sentiment for BCRX has remained ‘extremely bullish’ over the past three months and recently climbed to its strongest level of 2026 amid nearly a 300% surge in message volumes, with investors debating whether the after-hours rally reflected positioning ahead of a potential acquisition.<figure class="image"><img src="https://news.stocktwits-cdn.com/bcrx_ss_png_4999553778.webp" alt="bcrx ss.png" width="967" height="144"><figcaption>BCRX sentiment and message volume as of March 23 | Source: Stocktwits</figcaption></figure>One trader&nbsp;<a href="https://stocktwits.com/SCCT2FL/message/648340880">said</a>, “Somebody knows something. A $10 stock doesn’t just go up 10%+ for nothing after hours.” Meanwhile, another trader&nbsp;<a href="https://stocktwits.com/Iwillbuy/message/648308700">expects</a> a buyout to be announced as soon as Wednesday, in an all-cash offer.Some observers&nbsp;<a href="https://stocktwits.com/tkr/message/648180984">suggested</a> institutional positioning at lower levels supported the takeover narrative, arguing that entry around $9.7 signaled confidence in further upside and the possibility that larger pharmaceutical companies could emerge as bidders.<figure class="image"><img src="https://news.stocktwits-cdn.com/bcrx_sentiment_png_404b898eb7.webp" alt="bcrx sentiment.png" width="973" height="447"><figcaption>BCRX sentiment as of March 23 | Source: Stocktwits</figcaption></figure>Others&nbsp;<a href="https://stocktwits.com/Money_Mane/message/648056955">framed</a> possible price scenarios depending on whether a deal materializes, estimating the shares could reach $16-$18 in a buyout case, trade toward $13-$16 with continued execution, or fall toward $7-$9 if competition increases, with further downside possible if pipeline expectations weaken.&nbsp;However, not all views supported the takeover thesis. One user&nbsp;<a href="https://stocktwits.com/doublebtx/message/648310647">noted</a> that the company’s history suggested it may prefer acting as an acquirer rather than a target, while another argued that if investors had firm takeover insight, the stock would already be trading closer to $14-$15.&nbsp;“If the BO [buyout] speculation (if that even is what is happening) goes away, this certainly could drop back,”&nbsp;<a href="https://stocktwits.com/doublebtx/message/648126797">said</a> one user. “But I would just like to point out that even at these levels, this is not even trading at 4x current revs. So it is certainly not overvalued here with or without BO rumors.”<h2 class="st-heading-2">Orladeyo Anchors Growth Outlook</h2>The takeover speculation surfaced alongside improving pipeline visibility, highlighted earlier this month at the TD Cowen 46th Annual Health Care Conference. CEO Charlie Gayer said the company generated $601 million in revenue last year from Orladeyo, its oral preventive treatment for hereditary angioedema, and $214 million in non-GAAP operating profit.“Orladeyo is still the most differentiated product on the market because it’s the only oral prophylactic on the market today,” Gayer said, adding that half of the patients starting Orladeyo are switching from injectable prophylaxis therapies.The company also highlighted Navenibart, the late-stage hereditary angioedema therapy&nbsp;acquired with Astria, as a key driver of future franchise expansion. It also noted that the composition-of-matter patent protection for Orladeyo extends to 2040.Gayer added that the broader portfolio outlook remains strong: “We’re talking about a portfolio that we see growing at mid-teens in revenue well into the 2030s.”For updates and corrections, email newsroom[at]stocktwits[dot]com.

CANADA - 2025/10/14: In this photo illustration, the BioCryst Pharmaceuticals (Bio Cryst) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

BioCryst Stock Jumps After Hours On Big Pharma Suitor Buzz — Retail Sentiment Hits 2026 Peak

Betaville’s “uncooked” alert from last week flagged potential interest in BioCryst from a U.S.-based biopharma with a market cap above $15 billion.

Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today?

Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells 150,000 Shares of Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 150,000 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the completion of the...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells $1,372,500.00 in Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 150,000 shares of the company's stock in a transaction dated Monday, March 16th. The shares were sold at an...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 13.8% - Here's What Happened

BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 13.8% - Should You Buy...

Top Biotech Stocks To Keep An Eye On - March 16th

Danaher, Vertex Pharmaceuticals, Moderna, BioCryst Pharmaceuticals, ImmunityBio, argenex, and Abivax are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

BCRX
Biocryst Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BCRX News

BCRXBiocryst Pharmaceuticals Inc.